Critical Survey: Genelux (NASDAQ:GNLX) versus Q32 Bio (NASDAQ:QTTB)

Q32 Bio (NASDAQ:QTTB) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Volatility & Risk

Q32 Bio has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Genelux has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Q32 Bio and Genelux, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	1	1	6	1	2.78
Genelux	1	0	2	1	2.75

Q32 Bio currently has a consensus target price of $32.17, suggesting a potential upside of 269.31%. Genelux has a consensus target price of $20.00, suggesting a potential upside of 972.39%. Given Genelux’s higher probable upside, analysts clearly believe Genelux is more favorable than Q32 Bio.

Valuation and Earnings

This table compares Q32 Bio and Genelux”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74 million	4.85	$29.82 million	$3.34	2.61
Genelux	$10,000.00	8,437.26	-$32.15 million	($0.86)	-2.17

Q32 Bio has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Q32 Bio and Genelux’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	17.03%	15.24%
Genelux	N/A	-205.85%	-138.79%

Summary

Q32 Bio beats Genelux on 9 of the 13 factors compared between the two stocks.

About Q32 Bio

Q32 Bio is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms. The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.

About Genelux

Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.